This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Innovations of Magnus Munck Af Rosenschold
Introduction
Magnus Munck Af Rosenschold is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of metalloproteinase inhibitors. With a total of 2 patents to his name, his work has the potential to impact therapeutic applications significantly.
Latest Patents
His latest patents focus on hydantoin derivatives as metalloproteinase inhibitors. The inventions provide compounds of formula (I), wherein R, R, A, A, and B are defined in the specification. These patents detail processes for the preparation of these compounds, pharmaceutical compositions containing them, and their therapeutic uses. The compounds are particularly useful as MMP inhibitors, showcasing their potential in medical applications.
Career Highlights
Magnus is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca emphasizes the importance of innovation in drug development and the role of research in creating effective therapies.
Collaborations
He collaborates with talented individuals such as Balint Gabos and Michael Lundkvist, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Magnus Munck Af Rosenschold's contributions to the field of pharmaceutical sciences through his patents and collaborations highlight the importance of innovation in developing new therapies. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile